title: FEC mobilized stem cells for high-dose therapy in breast cancer patients. SB6 9401 Study Group.
abstract: The feasibility of mobilizing peripheral blood stem cells (PBSC) using anthracycline containing polychemotherapy and G-CSF on the first 50 patients randomized to the high-dose arm in the adjuvant SBG 9401 is investigated. The patients were treated with standard FEC (5-fluorouracil 600 mg/m2, epirubicin 60 mg/m2, cyclophosphamide 600 mg/m2) for two courses followed by a modified third FEC course with a C dose of 1200 mg/m2 supported with subcutaneous G-CSF (filgrastim) at 5 mg/kg followed by harvest around day 11. The mean yield of CD34+ cells per patient was 10.6x10(6)/kg (range 2.6-29.1). The side effects after the third course were low and only one patient developed an uncomplicated granulopenic fever. Our data indicated a correlation between number of transfused CD34+ cells and days to neutrophil and platelet recovery. In conclusion, the modified FEC regimen followed by G-CSF is a feasible method for PBSC mobilization in the adjuvant setting.
authors.affiliation: Department of Oncology, University Hospital, Uppsala, Sweden.
authors.forename: H
authors.initials: H
authors.lastname: Lindman
authors.forename: T
authors.initials: T
authors.lastname: Wiklund
authors.forename: H
authors.initials: H
authors.lastname: Holte
authors.forename: P
authors.initials: P
authors.lastname: Ljungman
authors.forename: C
authors.initials: C
authors.lastname: Blomqvist
authors.forename: G
authors.initials: G
authors.lastname: Kvalheim
authors.forename: M
authors.initials: M
authors.lastname: Bengtsson
authors.forename: M
authors.initials: M
authors.lastname: Höglund
authors.forename: N
authors.initials: N
authors.lastname: Wilking
authors.forename: J
authors.initials: J
authors.lastname: Bergh
mesh_terms: D018952:Antigens, CD34 / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D000069585:Filgrastim; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007937:Leukapheresis; D011994:Recombinant Proteins; D013234:Stem Cells / Q000276:immunology*
chemical_list: D018952:Antigens, CD34; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D015251:Epirubicin; D003520:Cyclophosphamide; D000069585:Filgrastim; D005472:Fluorouracil